Last reviewed · How we verify
Other atypical antipsychotic drugs — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Other atypical antipsychotic drugs (Other atypical antipsychotic drugs) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Other atypical antipsychotic drugs TARGET | Other atypical antipsychotic drugs | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Other atypical antipsychotic drugs CI watch — RSS
- Other atypical antipsychotic drugs CI watch — Atom
- Other atypical antipsychotic drugs CI watch — JSON
- Other atypical antipsychotic drugs alone — RSS
Cite this brief
Drug Landscape (2026). Other atypical antipsychotic drugs — Competitive Intelligence Brief. https://druglandscape.com/ci/other-atypical-antipsychotic-drugs. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab